EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer.
D000230:Adenocarcinoma / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D036183:Receptor, EphB2 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000276:immunology; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D036183:Receptor, EphB2